We describe a 14-year-old bone marrow transplant recipient who was anti-HBs-positive before the procedure and afterwards developed acute infection with hepatitis B virus (HBV). Liver biopsies taken while symptomatic showed portal fibrosis progressing to cirrhosis. The patient responded to lamivudine treatment with HBeAg seroconversion and significant regression of fibrosis. Although the source and timing of HBV exposure remain unclear, the potential for severe hepatitis B infection following bone marrow transplant warrants caution. This case demonstrates that a symptomatic HBV infection can occur in an immunocompromised patient who had originally been anti-HBs-positive.
Bone marrow transplant patients are susceptible to serious viral infections due to their immunocompromised status. Human herpesvirsuses, adenovirus and parvovirus B19 pose particular problems in these patients. In contrast, viruses such as measles, mumps, rubella and hepatitis B usually pose little risk, if the patient has been vaccinated against them. However, patients who are seropositive for anti-HBs from natural infection may harbor latent virus which can re-activate during the immunocompromised phase following bone marrow transplantation. [1] [2] [3] We describe an anti-HBs-positive female who developed acute hepatitis B following chemotherapy and bone marrow transplantation. She did not clear the virus spontaneously. Treatment with lamivudine resulted in HbcAg seroconversion and regression of fibrosis on liver biopsy. This case underscores the risk of significant HBV disease in an antiHBs-positive patient after immunosuppression.
Case report
A 14-year-old female, who was seropositive for anti-HBs from vaccination, developed acute myelogenous leukemia. On presentation she was found to be seronegative for HBsAg and for antibody to HIV 1/2 by screening assay. She was treated with chemotherapy (hydroxyurea, cytosine arabinoside, idarubicin, busulfan, cyclophosphamide, methotrexate and cyclosporine) and experienced remission of leukemia. She then underwent allogeneic BMT. Her donor, who was her brother, had also been previously vaccinated against HBV and was documented to be seronegative for HBsAg and anti-HBc but seropositive for antiHBs. One year post transplant and 3 months after cyclosporine immunosuppression had been tapered and then stopped, she developed acute hepatitis with marked elevation of serum aminotransferases (peak ALT 2064 U/l). At this time she was seropositive for HBsAg, HBeAg, antiHBc IgM, and HBV DNA, while being seronegative for anti-HBs and anti-HBe (Figure 1) . No antibodies to hepatitis A or C were detected. Liver biopsy taken at this time showed hepatitis (Figure 2a ) with generalized HBcAg immunostaining within hepatocytes (Figure 2c ). Immunostaining for HBsAg showed diffuse staining of hepatocyte plasma membranes in a 'honeycomb' pattern ( Figure 2b) .
As shown in Figure 1 , she remained seropositive for HBeAg and HBV DNA with elevated serum aminotransferases. Six months following the initial liver biopsy, a second liver biopsy revealed portal fibrosis with early cirrhosis, 'piecemeal' necrosis and abundant expression of hepatitis B core and surface antigen. Treatment with lamivudine 100 mg by mouth once daily was then started.
Following 1 month of treatment, she became seropositive for anti-HBe and seronegative for HBV DNA. After 9 months of lamivudine therapy, she became seronegative for HBeAg. Serum aminotransferases gradually returned to normal by 12 months after starting lamivudine. A third liver biopsy performed after 13 months of treatment revealed substantial improvement (Figure 3a) . Inflammation had resolved, and there was minimal residual fibrosis. There was reduced membrane immunostaining for HBsAg ( Figure 3b ) and only occasional nuclear positivity for HBcAg (Figure 3c ). Lamivudine treatment was stopped at the time of this biopsy. Repeat testing for HBV serology 3.5 months after discontinuation of treatment showed that anti-HBe was still detectable whereas HBV DNA was not detectable by the hybridization technique. Follow-up 18 months after stopping lamivudine revealed that the patient was in good health, with normal serum aminotransferases, bilirubin, albumin, and complete blood count. HBsAg and anti-HBe remained positive 18 months after stopping lamivudine.
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No anti-HBc was detected on retrospective testing of the patient's serum sample obtained before BMT. The titer of anti-HBs was found to be relatively low (14-23 IU/ml), although this level is still regarded as protective. She had received blood products in the management of her leukemia. Trace-back of all donors of blood or blood products administered to her was performed by the Canadian Blood Services, and most of these 177 donors made repeat donations which were confirmed as negative for hepatitis B viral markers, although at least one first-time donor could not be traced.
Discussion
This child who was initially seropositive for anti-HBs underwent BMT after standard chemotherapy for AML. Her allogeneic donor had been successfully vaccinated against hepatitis B. Although she was considered to have a protective level of anti-HBs antibodies, she developed acute hepatitis B upon withdrawal of immunosuppression for the BMT. The hepatitis was clinically severe and rapidly progressed to extensive fibrosis within approximately 7
Bone Marrow Transplantation months. She was treated with lamivudine and responded with serological conversion of HBeAg to anti-HBe, along with clearance of serum HBV DNA by hybridization assay. Follow-up liver biopsy showed significant histological improvement. This is the first report of a pediatric case of severe HBV infection following chemotherapy and BMT in an apparently immune host and possibly the first report to document resolution of hepatic fibrosis in a child treated with lamivudine.
This case raises important issues regarding HBV infection in BMT recipients. The occurrence of HBV-induced liver disease was unexpected in view of the patient being anti-HBs-positive and HBsAg-negative prior to BMT. The source and timing of HBV exposure in her remain uncertain. This does not appear to be a classic case of HBV reactivation following immunosuppression; this patient had no evidence of a previous HBV infection since anti-HBc was negative prior to transplantation. Transplant recipients with anti-HBs are considered immune because antibodies to HBsAg above 10 IU/ml are considered protective. However, with immunosuppression, 'HBV reactivation' has been described despite the presence of anti-HBs. [1] [2] [3] Sensitive PCR analysis has identified HBV DNA in both liver and blood of patients with anti-HBs. 4 Immunosuppression likely impairs T cell function, allowing for viral replication. 5 When immunosuppression is withdrawn, immune function resumes and may eliminate active viral infection.
This patient possibly had natural subclinical hepatitis B virus infection in early childhood, recovered and subsequently lost detectable titers of anti-HBc. More likely, the anti-HBs status of this patient was due to previous vaccination (as reported by patient history), with waning titers of anti-HBs. Low levels of anti-HBs may not withstand the immunosuppressive blunting of the anamnestic anti-HBs response. 1 Immunosuppression may lead to further decline in anti-HBs titer leaving the patient susceptible to HBV infection. Although this is the most likely explanation of the acute hepatitis in this patient, the source of HBV exposure remains unclear. The bone marrow donor was vaccinated for hepatitis B. Blood products for transfusion are screened for HBV, and individuals with a history of clinical hepatitis occurring after 10 years of age are not accepted as blood donors, in the absence of serological proof of hepatitis A. Therefore, blood transfusion is an unlikely source of infection. By careful history, this patient was not at risk for other sources of HBV infection.
This case may be compared with reports of HBV reactivation in anti-HBs-and anti-HBc-positive adults undergoing BMT, where the severity of liver disease with HBV reactivation following immunosuppression ranges from rapidly progressive hepatitis with cirrhosis to transient, asymptomatic elevation of serum aminotransferases. [1] [2] [3] 6 In our case, liver biopsies (performed 6 months apart) demonstrated chronic hepatitis progressing to extensive fibrosis, indicating a guarded prognosis.
Experience in the treatment of immunosuppressionrelated HBV infection is very limited. Treatment with interferon-␣ may adversely affect engraftment of the transplanted bone marrow. Lamivudine inhibits HBV reverse transcriptase and markedly reduces serum HBV DNA levels in cases of reinfection following liver transplant, AIDS, and chemotherapy. [7] [8] [9] One anti-HBs-positive patient with AIDS developed HBV reactivation following lamivudine withdrawal. Resumption of lamivudine led to clearance of HBV DNA and HBsAg with normalization of aminotransferases. 7 There has been a report of one patient with chemotherapy-induced HBV reactivation who experienced recovery on lamivudine. 8 Lamivudine treatment for chronic hepatitis B carries the risk of developing resistance to lamivudine (via YMDD mutants of HBV) or experiencing relapse of HBV infection upon cessation of treatment. 10, 11 The patient reported here had a favorable serological and histological response. Improved histological findings -and specifically, decreased fibrosis -have been reported previously after lamivudine treatment for hepatitis B after liver transplantation. 12 Our experience casts further doubt on the effectiveness of using marrow from HBV-vaccinated (anti-HBs-positive) donors to confer HBV immunity to HBsAg-positive bone marrow transplant recipients. 13 In our case, anti-HBs from the donor did not protect the recipient from HBV disease.
Thorough evaluation of HBV status in BMT donors and recipients is necessary. Anti-HBs-positive/HBsAg-negative serum does not guarantee immunity from HBV. The titer of antibody should always be determined. Presence of antiHBc should be checked. Severe HBV infection after chemotherapy should be preventable through effective vaccination, if circumstances allow. Lamivudine treatment may be effective in those cases which cannot be prevented.
